Company profile: Hibiskus Bio
1.1 - Company Overview
Company description
- Provider of early-stage development of TIR-199, a small-molecule cancer therapy and potent proteasome inhibitor from the syrbactin natural product family, discovered by founders Profs. Pirrung and Bachmann of the University of California, Riverside (UCR) and Michigan.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Hibiskus Bio
Novavax
HQ: United States
Website
- Description: Provider of vaccines and vaccine technologies for infectious diseases, including a recombinant nanoparticle COVID-19 vaccine with Matrix-M adjuvant; a Phase 2 COVID-influenza combination (CIC) vaccine; and the authorized R21/Matrix-M malaria vaccine. Also offers Matrix-M, a saponin-based adjuvant, and recombinant nanoparticle vaccine technology using engineered proteins.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Novavax company profile →
Y-mAbs Therapeutics
HQ: United States
Website
- Description: Provider of innovative cancer treatments and support services, including FDA-approved DANYELZA (naxitamab-gqgk) for relapsed or refractory high-risk neuroblastoma in bone or bone marrow; clinical trials for investigational therapies (naxitamab, omburtamab, GD2-SADA); expanded access programs; Y-mAbs Connect for access, insurance and financial support; and patient and family resources.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Y-mAbs Therapeutics company profile →
Asher Bio
HQ: United States
Website
- Description: Provider of cis-targeted cytokine immunotherapies that selectively activate CD8+ T cells for cancer and chronic viral infections. Pipeline includes AB248, a cis-targeted IL-2 in Phase 1a/1b for solid tumors; AB821, a CD8-targeted IL-21; AB359 for chronic viral infections including HBV; and cis-targeted cytokines to enhance CAR-T and other cell therapies by improving engraftment, persistence, and function.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Asher Bio company profile →
Theravectys
HQ: France
Website
- Description: Provider of a proprietary lentiviral vector platform for developing vaccines and immunotherapies to prevent and treat infectious diseases, cancers, and other conditions. Pipeline includes Lenti-HPV-07 (Phase 1) for HPV16/18-induced oropharyngeal and cervical cancers, Lenti-COVID intranasal vaccine for SARS-CoV-2 variants, and LV-DEN tetravalent T-cell dengue vaccine. Initial clinical focus includes HIV/AIDS.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Theravectys company profile →
Allogene Therapeutics
HQ: United States
Website
- Description: Provider of allogeneic CAR T cell therapies via the AlloCAR T Product Platform, developing investigational treatments for blood cancers, solid tumors, and autoimmune diseases: cemacabtagene ansegedleucel (CD19) for large B-cell lymphoma and chronic lymphocytic leukemia; ALLO-316 (CD70) for clear cell renal cell carcinoma; ALLO-329 (CD19/CD70) for autoimmune diseases; ALLO-715 (BCMA) and ALLO-605 (BCMA TurboCAR) for multiple myeloma.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Allogene Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Hibiskus Bio
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Hibiskus Bio
2.2 - Growth funds investing in similar companies to Hibiskus Bio
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Hibiskus Bio
4.2 - Public trading comparable groups for Hibiskus Bio
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →